• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Prognosis of patients with primary melanoma Stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    35709414.pdf
    Size:
    503.3Kb
    Format:
    PDF
    Description:
    Identified with Open Access button
    Download
    Authors
    Garbe, C.
    Keim, U.
    Amaral, T.
    Berking, C.
    Eigentler, T. K.
    Flatz, L.
    Gesierich, A.
    Leiter, U.
    Stadler, R.
    Sunderkötter, C.
    Tüting, T.
    Utikal, J.
    Wollina, U.
    Zimmer, L.
    Zouboulis, C. C.
    Ascierto, P. A.
    Eggermont, A. M. M.
    Grob, J. J.
    Hauschild, A.
    Sekulovic, L. K.
    Long, G. V.
    Luke, J. J.
    Michielin, O.
    Peris, K.
    Schadendorf, D.
    Kirkwood, J. M.
    Lorigan, Paul C
    Show allShow less
    Affiliation
    Department of Dermatology, Center for Dermatooncology, Eberhard Karls University of Tübingen, Tübingen, Germany
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Purpose: The first randomized trial of adjuvant treatment with checkpoint inhibitor in stage II melanoma reported a significant reduction in risk of tumor recurrence. This study evaluates two independent data sets to further document survival probabilities for patients with primary stage I and II melanoma. Patients and methods: The Central Malignant Melanoma Registry (CMMR) in Germany evaluated 17,544 patients with a primary diagnosis of stage I and II melanoma from 2000 to 2015. The exploratory cohort consisted of 6,725 patients from the Center for Dermato-Oncology at the University of Tübingen, and the confirmatory cohort consisted of 10,819 patients from 11 other German centers. Survival outcomes were compared with published American Joint Committee on Cancer version 8 (AJCCv8) stage I and II survival data. Results: For the two CMMR cohorts in stage IA compared with the AJCCv8 cohort, melanoma-specific survival rates at 10 years were 95.1%-95.6% versus 98%; 89.7%-90.9% versus 94% in stage IB; 80.7%-83.1% versus 88% in stage IIA; 72.0%-79.9% versus 82% in stage IIB; and 57.6%-64.7% versus 75% in stage IIC, respectively. Recurrence rates were approximately twice as high as melanoma-specific mortality rates in stages IA-IIA. Conclusion: The melanoma-specific survival rates in the two CMMR cohorts across stages I and II are less favorable than published in AJCCv8. This has important implications for the consideration of adjuvant treatment in this population.
    Citation
    Garbe C, Keim U, Amaral T, Berking C, Eigentler TK, Flatz L, et al. Prognosis of Patients With Primary Melanoma Stage I and II According to American Joint Committee on Cancer Version 8 Validated in Two Independent Cohorts: Implications for Adjuvant Treatment. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022.
    Journal
    Journal of Clinical Oncology
    URI
    http://hdl.handle.net/10541/625377
    DOI
    10.1200/jco.22.00202
    PubMed ID
    35709414
    Additional Links
    https://dx.doi.org/10.1200/jco.22.00202
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1200/jco.22.00202
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts.
    • Authors: Garbe C, Keim U, Suciu S, Amaral T, Eigentler TK, Gesierich A, Hauschild A, Heinzerling L, Kiecker F, Schadendorf D, Stadler R, Sunderkötter C, Tüting T, Utikal J, Wollina U, Zouboulis CC, Keilholz U, Testori A, Martus P, Leiter U, Eggermont AMM, German Central Malignant Melanoma Registry and the European Organisation for Research and Treatment of Cancer
    • Issue date: 2020 Aug 1
    • Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
    • Authors: Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N
    • Issue date: 2019 May
    • Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    • Authors: Agarwala SS, Neuberg D, Park Y, Kirkwood JM
    • Issue date: 2004 Apr 15
    • Novel adjuvant options for cutaneous melanoma.
    • Authors: Dimitriou F, Long GV, Menzies AM
    • Issue date: 2021 Jul
    • Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
    • Authors: Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA, KEYNOTE-716 Investigators
    • Issue date: 2022 Nov
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.